ESQlabs Announces the Launch of MPSlabs as a Dedicated Business Unit for leveraging modelling and simulation approaches for microphysiological systems.
Saterland, Germany, 8th of May, 2024 — ESQlabs GmbH, a leader in biosimulation services and solutions, announces the launch of a new business unit (BU) called MPSlabs. As ESQlab’s first BU, MPSlabs will drive innovation in digital twin technologies for microphysiological systems (MPS) and organ-on-chip (OoC) platforms. The BU concept is an initiative to incubate new technology ideas in life-sciences to streamline and optimize the solutions ESQlabs delivers to clients for their decision-making process in R&D.
Leading Edge in Biotechnology
Headed by Dr. Christian Maass, with more than 10 years of track record in integrating MPS and organ-on-chip technologies as custom Modelling and Simulation services, MPSlabs commits to improving predictions of in-human situations using quantitative biological data from MPS and OoC experiments. MPSlabs – a purely digital lab – stands on 3 pillars:
- Model-based architecture and design of MPS devices
- Optimization of operational protocols
- Integration of MPS data into human digital twins for translation and prediction of in-human situations.
Leadership and Collaborative Synergy
“I am super excited and grateful to lead MPSlabs, leveraging the support from ESQlabs to transform healthcare through innovative technologies. This synergy aims to improve the prediction of in-human drug behavior – without the use of animals” stated Dr. Christian Maass. MPSlabs will work as an autonomous unit within ESQlabs, using its existing strengths to integrate cutting-edge research with established expertise.
“The launch of MPSlabs marks a significant step in developing ESQlabs as a company and the MPS and OoC community. It aligns with our mission to generate innovation through our core expertise and provide solutions that enable earlier and safer go/no-go decisions for our clients” said Dr. Stephan Schaller, CEO of ESQlabs. “We are committed to supporting MPSlabs in setting new industry standards and advancing drug development ethics and efficacy.”
Impactful Ventures of MPSlabs
MPSlabs has already garnered significant traction through successful collaborations and projects.
Liver-Chip Applications
A groundbreaking partnership with Bayer Consumer Health (https://www.bayer.com/media/en-us/new-organ-on-chip-pilot-seeks-to-reduce-animal-testing-in-consumer-health-industry/) resulted in the development of a gut-liver-placenta-chip for predicting compound PK in pregnant women.
Further, the innovative work of MPSlabs analyzed more than 30 unique compounds, demonstrating an improved prediction power of human kinetics of up to 86% (https://www.biorxiv.org/content/10.1101/2024.03.28.587123v1). This work is currently under further development in a liver-chip project with another pharma partner.
Brain-Chip Applications
As partner in a recently funded EIC Transition Grant (EU), MPSlabs is focusing on finding optimal cures for glioblastoma in children. Additionally, MPSlabs is leading a project funded by the Berlin Animal Protection Office to predict the partitioning of compounds across the blood-brain barrier.
“These case studies are just a snapshot of the range of our capabilities, with the potential to tailor our approach to clients-needs and to include other organs such as the gut, kidney, or heart.”, says Dr. Maass.
Forward-Looking Aspirations
With MPSlabs, ESQlabs reinforces its position as an innovator in biotech, advancing the potential of digital twins and MPS technologies to refine drug development and personalized medicine. MPSlabs and its digital twin technology platforms will also be applied in next-generation chemical risk assessment and to support the development of Non-Animal Methodologies (NAMs).
For further details or to arrange an interview with Dr. Christian Maass, please contact:
Contact Information
Dr. Christian Maass
Lead, MPSlabs
This release contains forward-looking statements based on current expectations. Actual results may vary due to numerous factors.
Get in touch now
Contact
ESQlabs GmbH | Am Sportplatz 7 | 26683 Saterland | Germany
Tel. +49 151 / 58559070 | info@esqLABS.com
This site does not use cookies to track your personal information